Neumora Therapeutics, Inc. NMRA announced that the FDA has placed a clinical hold on the phase I study, which evaluated NMRA-266, its positive allosteric modulator (PAM) of the M4 muscarinic receptor, ...
Hosted on MSN
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment
Neumora Therapeutics, Inc. ((NMRA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 9, Neumora Therapeutics initiated a Phase 1 single-ascending ...
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 16, Mizuho increased its price target for Neumora Therapeutics, Inc. (NASDAQ:NMRA) from $4 to ...
As of July 4, 2024, the average one-year price target for Neumora Therapeutics is $25.76/share. The forecasts range from a low of $22.22 to a high of $30.45. The average price target represents an ...
QA1 recently signed on to sponsor NMRA’s popular True Street category, which is presented byMuscle Mustangs & Fast Fordsand takes place at each NMRA Keystone Automotive Ford Nationals event. QA1, ...
Saveen Semage, the Chief Executive Officer (CEO) of the National Medicines Regulatory Authority (NMRA), resigned with immediate effect yesterday, citing threats to his life. On May 9, CCTV in his home ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback